Compare BGDE & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGDE | MIRA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 37.1M |
| IPO Year | 2013 | 2023 |
| Metric | BGDE | MIRA |
|---|---|---|
| Price | $6.87 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 58.7K | ★ 1.4M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,754,085.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.58 | $0.60 |
| 52 Week High | $11.69 | $2.45 |
| Indicator | BGDE | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 45.17 |
| Support Level | $5.81 | $0.72 |
| Resistance Level | $6.57 | $0.82 |
| Average True Range (ATR) | 0.58 | 0.08 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 14.21 | 8.21 |
Big Digital Energy Inc, formerly Mawson Infrastructure Group Inc is focused on digital infrastructure platforms. It designs, builds and operates next-generation digital infrastructure platforms for enterprise customers and for its own purposes. The company provides services spanning AI, HPC, digital assets including Bitcoin mining, and other intensive compute applications. The company delivers both self-mining operations and colocation services to enterprise customers with a vertically integrated infrastructure model built for scalability and efficiency. The company also has an energy management business, which utilizes software and analysis, to generate revenue by participating in energy management programs. It operates as one energy management and digital asset mining segment.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.